1. Scrip

Takeda Sees Mainstays Tiding It Over Upcoming Expiries

Velcade First Up

 
• By Ian Haydock

As Takeda reported what its CEO described as "a remarkable year," the company sees itself as well positioned to ride out the expiries over the next few years of exclusivity for several big-selling products, as it looks to mainstays and more organic growth to tide it over the "temporary headwinds."

Takeda Tokyo HQ
Japan's biggest pharma firm expecting JPY1tn core operating profit • Source: Ian Haydock/Scrip

Takeda Pharmaceutical Co. Ltd. expects a favourable foreign exchange impact from the weak yen to help drive its performance in the current fiscal year, which, along with continued growth for mainstays, is seen helping it face down the first of several upcoming product expiries over the next few years.

These positive factors are expected to fully offset the US loss of exclusivity of multiple myeloma drug Velcade (bortezomib) during the current financial year which started on 1 April, as well as the impact of the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia